Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
The leveraged fund, SOXL, jumped sharply in intraday trading after a report that Google ordered millions of tensor processing units to be manufactured at Intel’s foundry capacity in 2028.
THE APEX TIMES
THE APEX TIMES
Yahoo Finance on Monday framed Broadcom as one of Chase Coleman’s Tiger Global “best stocks,” citing a bullish Bank of America update dated June 4. BofA raised its Broadcom price target from $450 to $530, pointing to accelerating AI-driven demand and continuing upside in both semiconductors and software.
THE APEX TIMES
At Microsoft Build 2026, Mustafa Suleyman framed the company’s AI program as a push to become one of the world’s leading AI research labs, pairing that ambition with a new family of in-house MAI models across reasoning, coding, image generation, voice, and transcription.
THE APEX TIMES
The VMware Tanzu unit said it is releasing its largest set of Spring security updates in 23 years and expanding enterprise support that separates security fixes from broader changes.
THE APEX TIMES
Investors and developers are watching Monday’s WWDC Keynote for signs that Apple’s next software wave, including new Apple Intelligence and a potential Siri upgrade, can narrow the company’s AI gap.
THE APEX TIMES
The stock’s 44% May gain was fueled by Ford Energy and a grid-scale battery bet tied to data-center growth, but June weakness underscores how much the market is still weighing Ford’s uneven auto earnings.
THE APEX TIMES
The approval moves the long-delayed 777-9 toward its broader FAA-supervised certification work, though type certification and ETOPS approval remain to be completed.
THE APEX TIMES
Nvidia CEO Jensen Huang said the company’s Vera CPU will use SK hynix DRAM as both firms plan for a heavier second half of 2026 and into next year, underscoring how crucial memory supply has become for “AI factory” builds.
THE APEX TIMES
Eli Lilly’s latest clinical readouts across tirzepatide, the investigational retatrutide and oral GLP-1 orforglipron helped reinforce a bullish view after the American Diabetes Association meeting in New Orleans.
